About half of those taking Belviq in combination with a light exercise routine are losing 8 to 12 % of their weight. For someone weighing 250 lbs, that translates to 20 to 25 lbs. That greatly reduces the risk of stroke, cardiac arrest, and other obesity-related conditions. Moreover, Belviq has been shown to reduce blood-glucose levels, helping those with Diabetes, Type 11. It has also shown promise for those wanting to quit smoking. Side effects are few and mild.
F * 4157 New drug for marketing approval in Taiwan
2014/03/13 10:00 Kui Heng Network reporter Zhang Xuhong Taipei
Taiwan's biotech industry to write a new page ! Drug development quotient F * Taigen( 4157 ) , announced the Ministry of Health and Welfare Food and Drug Administration (TFDA) approval Taigen Biotechnology R & D of Nai Nuosha Star (Nemonoxacin, Tai Gitzo ®) oral dosage forms listed first in Taiwan TFDA examined by a new compound developed drug people .
Tai Gitzo ® approved for listing in Taiwan , its manufacture by the United States ( 1795 ) OEM sales team established by the King too , due to the Southeast Asian region , except for Singapore and Malaysia , but also recognize Taiwan drug card , so King will also be application for listing matters Southeast Asian market as soon as possible .
F * 4157Taigen said Tai Gitzo ® is a new non-fluorinated quinolone antibacterial drugs , there are two kinds of oral and injectable formulations . Taigen has completed clinical trials of oral formulations multinational multi- center clinical trial 1,282 subjects prove its safety and efficacy. Clinical trials proved Tai Gitzo ® can be effective against several drug-resistant bacteria , such as methicillin-resistant Staphylococcus aureus (MRSA), a quinolone resistant MRSA, as well as quinolone resistant Streptococcus pneumoniae and other stubborn bacteria. Because of that it has a broad spectrum, and drug design is not easy for bacteria to mutate , suitable as first-line therapy.
F * 4157 Taigen made in 2004 from Procter & Gamble (P & G) in the pharmaceutical sector Tai Gitzo ® authorized to take over from the clinical Phase Ia, actively developing patented clinical development plans and pharmaceutical manufacturing process of the follow-up of the indications , the extension of patent protection for life global patent owned up to 173 , patent protection up to 2029.
Good news from Taiwan( Google translate)
F * Taigen subsidiary奈诺沙star review of inspection and registration permit oral dosage forms of drugs through
2014/03/13 10:26 SysJust
Stock Material Information Notice
(4157) F * Taigen - on behalf of the major subsidiaries Taigen Biotechnology Co., Ltd. Notice Nainuo Sha Star oral dosage forms (Nemonoxacin ) , review by inspection and registration of new drugs (NDA) license
1 Date of occurrence : 103/03/12
2 Company Name: Taigen Biotechnology Co., Ltd.
(3) the relationship with the company [ Enter Company or its subsidiaries ] : affiliates
4 mutual shareholding ratio : 100%
5 media Name: NA
6 reported content : NA
7 occur reason : the Ministry of Health and Welfare Food Drug Administration (TFDA) review by Taigen Biotechnology Co., Ltd. R & D奈诺沙Star (Nemonoxacin ) oral dosage form drug inspection and registration (NDA).
8 Workaround: Manufacturing will continue to be listed on the pharmaceutical and ready to work.
9 other matters that :
(1 )奈诺沙star after listing in Taiwan listed tests to be performed ( ie, Phase IV trial).
( 2 ) Nainuo Sha star for a new generation of fluorine quinolones antibiotics can be effective against the growing proliferation of drug-resistant bacterial infections.
Nai Nuosha star in the United States has completed the community-acquired pneumonia and diabetic foot infections are indications two Phase II clinical trials , and by the U.S. FDA granted " fast-track " (Fast Track) treatment , as belonging to fight drug-resistant bacteria " anti-infective products" (Qualified Infectious Disease Product, referred QIDP) qualifications, obtained permission to sell an additional five years alone , plus the New Chemical Entity NCE ( innovative compounds ) of five-year monopoly period to up to 10 years .
奈诺沙star in Taiwan and China has completed Phase III clinical trials of oral formulations , and in March 2013 and April TFDA to Taiwan and China respectively
2012-09-07 01:17 工商時報 【記者涂志豪／台北報導】
蘋果及三星專利戰方興未艾，蘋果龐大晶圓代工訂單是否流向台積電等其它晶圓代工廠，一直是半導體業界及法人圈熱門話題。而根據業界人士透露，台積電與蘋果間已經「達成一定程度的共識」，蘋果ARM應用處理器在明年導入ARM Cortex A15架構後，將會委由台積電以20奈米製程代工。
蘋果目前採用在iPhone、iPad、Apple TV中的A5/A5X處理器，都屬於ARM Cortex A9核心，而即將推出的iPhone 5內建處理器，雖然名稱仍未確定，市場認為可能是A5-2或A6，但仍採用Cortex A9核心，所以與A5/A5X的架構相同，都由三星以32奈米代工量產。
而台積電明年將拿下蘋果次世代ARM應用處理器訂單，屬於新一代的ARM Cortex A15架構，以運算效能來看，雙核心Cortex A15的效能已等同於四核心的Cortex A9。由於台積電已完成Cortex A15的授權及20奈米試產，因此蘋果若決定與台積電團隊合作，已經沒有技術上的問題，可說是水到渠成。
Money Can’t Buy Apple This Supplier’s Love
By Aabha Rathee | More Articles
August 29, 2012
Apple (NASDAQ:AAPL) reportedly offered Taiwan Semiconductor Manufacturing Co. (NYSE:TSM) more than $1 billion to become a dedicated chip producer for the iPhone maker, but was denied. TSMC has said it intends to keep its interests in the rapidly growing smartphone market open. The company also denied an investment bid from Qualcomm (NASDAQ:QCOM), according to Bloomberg.
Don’t Miss: Who is Apple’s New FRIEND?
Currently, Apple relies on Samsung for the A-series chips used in its mobile devices, an increasingly uncomfortable scenario considering the intense rivalry the two share in the smartphone market and the legal confrontations they are involved in as a result. Samsung is also a supplier of displays and other device components for Apple.
TSMC, the world’s largest custom chip maker, already supplies Apple with iPhone and iPad chips through foundry services for Broadcom (NASDAQ:BRCM), CSR, Cirrus Logic (NASDAQ:CRUS), and Qualcomm.
While TSMC chairman Morris Chang told investors last month he would be happy to devote one or two factories to a single customer, the conditions in the separate deals from Apple and Qualcomm appear to have been unacceptable. Chief financial officer Lora Ho also said that dedicating a plant to a single product or customer was risky, since the client or technology could change.
“You have to be careful. Once that product migrates, what are going to do with that dedicated fab?” Ho said. “We would like to keep the flexibility.”
Here is the link in English: http://wallstcheatsheet.com/stocks/money-cant-buy-apple-this-suppliers-love.html/?ref=YF